Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06562790
Registration number
NCT06562790
Ethics application status
Date submitted
18/08/2024
Date registered
20/08/2024
Date last updated
11/05/2025
Titles & IDs
Public title
Study of Gamma PN3 in the Elderly
Query!
Scientific title
A Phase 1, Randomised, Active-controlled, Blinded, Dose-ranging Study of the Safety, Tolerability, and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine (Gamma-PN3) in Elderly Participants
Query!
Secondary ID [1]
0
0
GPNV-006
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pneumonia, Pneumococcal
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Gamma PN3
Treatment: Other - Prevnar
Experimental: Gamma-PN3 - 2 doses on Days 1 and 29
Active comparator: Prevnar - 1 dose on Day 1 and saline placebo on Day 29.
Treatment: Other: Gamma PN3
500, 1000 or 1500 µg by IM injection on Days 1 and 29
Treatment: Other: Prevnar
1 dose on Day 1 and saline placebo on Day 29
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adverse events
Query!
Assessment method [1]
0
0
Spontaneous and diary recorded events
Query!
Timepoint [1]
0
0
57 days
Query!
Primary outcome [2]
0
0
Geometric fold increase in IgG titre
Query!
Assessment method [2]
0
0
Day 29 / Day 1 and Day 57/Day 1 geometric fold increase in IgG titre
Query!
Timepoint [2]
0
0
56 days
Query!
Secondary outcome [1]
0
0
Geometric fold increase in OPA titre to 36 serotypes of S. pneumoniae
Query!
Assessment method [1]
0
0
Day 29 / Day 1 and Day 57/Day 1 geometric fold increase in opsonophagocytic titre
Query!
Timepoint [1]
0
0
56 days
Query!
Secondary outcome [2]
0
0
Geometric fold increase in IgA
Query!
Assessment method [2]
0
0
Day 29 / Day 1 and Day 57/Day 1 geometric fold increase in serum and mucosal IgA
Query!
Timepoint [2]
0
0
56 days
Query!
Secondary outcome [3]
0
0
Memory B cells
Query!
Assessment method [3]
0
0
Memory B cell count
Query!
Timepoint [3]
0
0
56 days
Query!
Secondary outcome [4]
0
0
Rate of community acquired pneumonia
Query!
Assessment method [4]
0
0
Number of participants with community acquired pneumonia
Query!
Timepoint [4]
0
0
1 year
Query!
Eligibility
Key inclusion criteria
1. Male or female volunteers aged 70 years and over at Screening.
2. In stable good general health as determined by the outcome of medical history, physical examination, and clinical judgement by the Investigator. Chronic stable non-inflammatory conditions such as hypertension, hyperlipidemia, well-controlled type 2 diabetes, stable asthma, controlled psychiatric conditions such as anxiety or depression, stable ischemic heart disease with heart failure not greater than NYHA Grade 1 and 2 are permitted, as determined by the Investigator.
3. Willing and able to give voluntary written informed consent before screening assessments commence.
4. Vital signs within the following ranges (inclusive):
• Body temperature 35.5 to 37.7°C
* Heart rate 50 to 100 beats per minute although atrial fibrillation is allowed.
* Respiratory rate 12 to 22 breaths per minute
* Systolic blood pressure 90 to 160 mmHg
* Diastolic blood pressure 50 to 95 mmHg
5. 12-lead ECG parameters within the following ranges:
• QTcB & QTcF - males =450 msec. females =470 msec
* PR 100 to 240 msec inclusive
* Heart rate (HR) 50 to 100 beats per minute (bpm) inclusive; atrial fibrillation is allowed.
6. Willing and able to communicate with the Investigator and study team and understands the requirements of the study.
7. Willing and able to undertake the study visits and all assessments, including possessing a suitable device and access to the internet for using the web-based electronic diary (e.g., smartphone, tablet, or computer) and able to use the device for this purpose.
8. Vaccinated against severe acute respiratory syndrome corona virus 2 (SARS-CoV-2; COVID-19) with a minimum of a prime and boost vaccinations.
Query!
Minimum age
70
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* 1. History of a previous Pneumovax 23® vaccination in last 12 months. 2. History of a previous Prevenar 13® or Prevenar 20® vaccination in last 12 months.
3. Positive serology blood test for human immunodeficiency virus (HIV) antibodies, hepatitis B virus (HBV) surface antigen or Hepatitis C virus (HCV) antibodies. Positive serology to Hepatitis C due to previous successfully treated infection with negative polymerase chain reaction (PCR) is not exclusionary.
4. Infectious disease including but not limited to COVID-19 and influenza within 30 days before Screening and any time between Screening and Day 1 first dose, as this may confound immune response to study vaccine.
5. Liver function tests (including aspartate aminotransferase [AST], alanine aminotransferase [ALT], bilirubin) >1.5 upper limit of normal (ULN).
6. Clinically significant abnormalities in laboratory tests (biochemistry, haematology), physical examination, or 12-lead ECG during the Screening period that, in the opinion of the Investigator, would affect immune response to vaccination and/or ability to fully participate in the study and/or not be in the individual's best interest to participate in the study. One re-test per abnormality is permitted.
7. Participation in another clinical study of any investigational or licensed product (including investigational COVID-19 vaccines, drugs, medical devices) or medical procedure within 4 weeks from last study visit before screening.
8. Plan to have a vaccine during the study period including COVID-19 booster. 9. Have had a live vaccine within three months of the first dose of study product or any other vaccine (including any COVID-19 vaccine) within 28 days of the first dose of study product.
Examples of live vaccines include, but are not limited to the following: measles, mumps, rubella, chicken pox/zoster (Zostavax; Shingrix is allowed), monkeypox, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid (oral) vaccines. Seasonal influenza vaccines for injection are generally killed virus vaccines and are permitted if administered at least 28 days before the first dose of study treatment and not during the enrollment or the study period. However, intranasal influenza vaccines are live attenuated vaccines and are not permitted within three months of first dose.
10. Have received blood or blood-derived products in the last three months before screening, which might interfere with assessment of the immune response.
11. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the last six months before screening; or long-term systemic corticosteroid therapy (prednisone at a dose of 5mg daily or equivalent for more than two consecutive weeks within the last month before screening, depot or intraarticular steroids within 3 months before screening).
12. A systemic inflammatory condition such as rheumatoid arthritis or inflammatory bowel disease.
13. Any medical condition requiring immunosuppressive therapy. 14. History of severe allergic reaction e.g., severe cutaneous adverse reaction or anaphylaxis to any medicinal product or to any of the study treatments, including excipients.
15. Current alcohol abuse (> 21 U/week for men and 14 U/week for women), substance dependence including nicotine/tobacco smoking (defined as more than 5 cigarettes or tobacco/nicotine equivalent per day; smoking or vaping will not be permitted while at the study unit), any use of illicit drugs or other addiction which might interfere with the ability to comply with study procedures in the opinion of the Investigator; positive drugs of abuse screen (tricyclic antidepressants, opioids, and benzodiazepines are not exclusionary if prescribed by a physician and consistent with medical history) or positive alcohol breath test at Screening or pre-dose. One re-test permitted for drugs of abuse screen where justified (e.g., false positive suspected).
16. Clinically significant chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion. Examples include congestive heart failure NHYA Grade 3 or 4, COAD with breathlessness interfering with daily activities; severe psychiatric conditions, poorly controlled asthma or diabetes 17. Any chronic medical condition e.g., asthma, gout, which is likely to need systemic corticosteroid therapy during the study.
18. Renal impairment requiring dialysis 19. Identified as a site employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife or de facto and their children, adopted or natural) of the site employees or the Investigator.
20. Poor venous access making scheduled blood sampling likely to be unsuccessful
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/08/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
31/03/2025
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
105
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
CMAX Fusion - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
5065 - Adelaide
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GPN Vaccines
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Phase 1 double- blind randomised active comparator dose escalating study of Gamma PN3 in the elderly
Query!
Trial website
https://clinicaltrials.gov/study/NCT06562790
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Paul Rolan, MD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
0405670420
Query!
Fax
0
0
Query!
Email
0
0
paul@gpnvaccines.com
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06562790
Download to PDF